Investor Relations

Overview

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.

For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.

View our corporate deck. 

Share Price
Price
Change
Current Share Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Half Year Report 2020

 

View Here

Corporate Presentation 

 

View Here

Cash at PureTech Parent Level

$387.2M Cash Equivalents and Short-Term Investments at PureTech Parent Level as of September 30, 20201

Analyst Coverage

1. PureTech Level Cash Reserves at September 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $372.0 million and held at PureTech LYT Inc., our internal pipeline, of $15.2 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of $38.3 million held at Controlled Founded Entities which are not wholly owned.